NYSE · Healthcare · Drug Manufacturers - General
Price at previous close. Open the live page for real-time data.
| Market cap | $402.35B |
| P/E ratio | 111.00908181368507 |
| P/B ratio | 14.690063228481034 |
| P/S ratio | 6.404936868240501 |
| Dividend yield | 2.96% |
| Return on equity | — |
| Net margin | 5.8% |
| EPS (TTM) | — |
| Beta | 0.309 |
| 52-week range | $181.73 – $244.81 |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREO…
What is AbbVie Inc.'s P/E ratio?
AbbVie Inc.'s trailing price-to-earnings (P/E) ratio is 111.0.
Does AbbVie Inc. pay a dividend?
Yes — the trailing dividend yield is approximately 2.96%.
What is ABBV's market capitalisation?
AbbVie Inc.'s market cap is approximately $402.35B.
Educational data only — not financial advice. Figures from Financial Modeling Prep, updated periodically. Verify before acting.